



UNITED STATES PATENT AND TRADEMARK OFFICE

I, Susan ANTHONY BA, ACIS,

Director of RWS Group Ltd, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.
2. That the translator responsible for the attached translation is well acquainted with the German and English languages.
3. That the attached is, to the best of RWS Group Ltd knowledge and belief, a true translation into the English language of the specification in German filed with the application for a patent in the U.S.A. on 16 April 2004 under the number 10/825,862.
4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.

For and on behalf of RWS Group Ltd

The 21st day of September 2005

FEDERAL REPUBLIC OF GERMANY

[Eagle crest]

**Priority Certificate
for the filing of a Patent Application**

File Reference: 103 18 611.5

Filing date: 24 April 2003

Applicant/Proprietor: elbion AG,
01445 Radebeul/DE

Title: 4-, 6-, or 7-hydroxyindoles with N-oxide groups and the use thereof
as therapeutic agents

IPC: C 07 D, A 61 K, A 61 P

**The attached documents are a correct and accurate reproduction of the original
submission for this Application.**

Munich, 26 February 2004

German Patent and Trademark Office

The President

[Seal of the German Patent
and Trademark Office]

pp

[signature]

Klostermeyer

WEICKMANN & WEICKMANN

Patentanwälte

European Patent Attorneys • European Trademark Attorneys

DIPL.-ING.	H. WEICKMANN (bis 31.1.01)
DIPL.-ING.	F.A. WEICKMANN
DIPL.-CHEM	B. HUBER
DR.-ING.	H. LISKA
DIPL.-PHYS.DR.	J. PRECHTEL
DIPL.-CHEM.DR.	B. BÖHM
DIPL.-CHEM.DR.	W. WEISS
DIPL.-PHYS.DR.	J. TIESMEYER
DIPL.-PHYS.DR.	M. HERZOG
DIPL.-PHYS.	B. RUTTENSPERGER
DIPL.-PHYS.DR.-ING.	V. JORDAN
DIPL.-CHEM.DR.	M. DEY
DIPL.-FORSTW.DR.	J. LACHNIT

Our reference:
30369P DE/WWpu

Applicant:
elbion AG
Meißner Straße 191

01445 Radebeul

**4-,6- or 7-Hydroxyindoles with N-oxide groups and the
use thereof as therapeutic agents**

**4-,6- or 7-Hydroxyindoles with N-oxide groups and the
use thereof as therapeutic agents**

Description

5

The invention relates to substituted 4-,6- or 7-hydroxyindoles with N-oxide groups, processes for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these
10 compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and
15 lymphocytes) by the compounds of the invention.

Activation of cell membrane receptors by transmitters leads to activation of the second messenger system. Adenylate cyclase synthesizes the active cyclic AMP
20 (cAMP) and cyclic GMP (cGMP) respectively from AMP and GMP. cAMP and cGMP lead for example in smooth muscle cells to relaxation, and in inflammatory cells to inhibition of mediator release and synthesis. The second messengers cAMP and cGMP are degraded by
25 phosphodiesterases (PDE). To date, 11 families of PDE enzymes (PDE1-11) are known and differ through their substrate specificity (cAMP, cGMP or both) and the dependence on other substrates (e.g. calmodulin). These isoenzymes have different functions in the body and are
30 expressed differently in individual cell types (Beavo, J.A., Conti, M. and Heasley, R.J., Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 1994, 46:399-405; Hall, I.P., Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses,
35 Br. J. clin. Pharmacol. 1993, 35:1-7). Inhibition of the various PDE isoenzyme types results in accumulation of cAMP or cGMP in cells, which can be utilized therapeutically (Torphy, T.J., Livi, G.P., Christensen,

S.B. Novel Phosphodiesterase Inhibitors for the Therapy of Asthma, Drug News and Perspectives 1993, 6:203-214).

5 The predominant PDE-isoenzyme in cells important for allergic inflammations (lymphocytes, mast cells, eosinophilic granulocytes, macrophages) is that of type 4 (Torphy, J. T. and Undem, B. J., Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991, 46:512-523). Inhibition of PDE 4
10 by suitable inhibitors is therefore regarded as an important approach to the therapy of a large number of allergically induced disorders (Schudt, Ch., Dent, G., Rabe, K, Phosphodiesterase Inhibitors, Academic Press London 1996).

15 An important property of phosphodiesterase 4 inhibitors is inhibition of the release of tumor necrosis factor α (TNF α) from inflammatory cells. TNF α is an important proinflammatory cytokine which influences a large
20 number of biological processes. TNF α is released for example from activated macrophages, activated T lymphocytes, mast cells, basophils, fibroblasts, endothelial cells and astrocytes in the brain. It has itself an activating effect on neutrophils,
25 eosinophils, fibroblasts and endothelial cells, whereby various tissue-damaging mediators are released. The effect of TNF α in monocytes, macrophages and T lymphocytes is increased production of further proinflammatory cytokines such as GM-CSF (granulocyte-
30 macrophage colony-stimulating factor) or interleukin-8. Owing to its proinflammatory and catabolic effect, TNF α plays a central role in a large number of disorders such as inflammations of the respiratory tract, inflammations of the joints, endotoxic shock, tissue
35 rejections, AIDS and many other immunological disorders. Thus, phosphodiesterase 4 inhibitors are likewise suitable for the therapy of such disorders associated with TNF α .

Chronic obstructive pulmonary diseases (COPD) are widespread in the population and also have great economic importance. Thus, COPD disorders are the cause of about 10-15% of all illness costs in the developed countries, and about 25% of all deaths in the USA are attributable to this cause (Norman, P.: COPD: New developments and therapeutic opportunities, Drug News Perspect. 11 (7), 431-437, 1998). The WHO estimates that COPD will become the third-commonest cause of death in the next 20 years.

The pathological condition of chronic obstructive pulmonary diseases (COPD) encompasses various pathological conditions of chronic bronchitis with the symptoms of coughing and expectoration, and progressive and irreversible deterioration in lung function (expiration is particularly affected). The course of the disease is episodic and often complicated by bacterial infections (Rennard, S. I.: COPD: Overview of definitions, Epidemiology, and factors influencing its development. Chest, 113 (4) Suppl., 235S-241S, 1998). There is a steady decline in lung function during the disorder, the lung becomes increasingly emphysematous, and the patients' breathing difficulty becomes obvious. This disorder markedly impairs the patients' quality of life (shortness of breath, low exercise tolerance) and significantly shortens their life expectancy. Besides environmental factors, the main risk factor is smoking (Kummer, F.: Asthma and COPD. Atemw.-Lungenkrkh. 20 (5), 299-302, 1994; Rennard, S. I.: COPD: Overview of definitions, Epidemiology, and factors influencing its development. Chest, 113 (4) Suppl., 235S-241S, 1998) and thus men are affected distinctly more frequently than are women. However, this picture will change in the future due to the alteration in lifestyles and the increase in the number of female smokers.

Current therapy aims only to alleviate the symptoms without affecting the causes of the progression of the

disorder. The use of long-acting beta2 agonists (e.g. salmeterol), possibly in combination with muscarinergic antagonists (e.g. ipratropium), improves lung function through bronchodilatation and is routinely employed
5 (Norman, P.: COPD: New developments and therapeutic opportunities, Drug News Perspect. 11 (7), 431-437, 1998). Bacterial infections play a large part in the episodes of COPD and need antibiotic treatment (Wilson, R.: The role of infection in COPD, Chest, 113 (4)
10 Suppl., 242S-248S, 1998; Grossman, R.F.: The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest, 113 (4) Suppl., 249S-255S, 1998). Therapy of this disorder is currently unsatisfactory, especially in relation to the
15 continuous decline in lung function. New therapeutic approaches acting on mediators of inflammation, proteases or adhesion molecules might be very promising (Barnes, P.J.: Chronic obstructive disease: new opportunities for drug development, TIPS 10 (19), 415-
20 423, 1998).


Irrespective of the bacterial infections complicating the disorder, a chronic inflammation is found in the bronchi and is dominated by neutrophilic granulocytes.
25 The mediators and enzymes released by neutrophilic granulocytes are thought inter alia to be responsible for the observed structural changes in the respiratory tract (emphysema). Inhibition of the activity of neutrophilic granulocytes is thus a rational approach
30 to the prevention or slowing down of the progression of COPD (deterioration in parameters of lung function). An important stimulus for the activation of granulocytes is the proinflammatory cytokine TNF α (tumor necrosis factor). Thus, it is known that TNF α stimulates the
35 formation of oxygen free radicals by neutrophilic granulocytes (Jersmann, H.P.A.; Rathjen, D.A. and Ferrante, A.: Enhancement of LPS-induced neutrophil oxygen radical production by TNF α , Infection and Immunity, 4, 1744-1747, 1998). PDE4 inhibitors are able

to inhibit very effectively the release of TNF α from a large number of cells and thus suppress the activity of neutrophilic granulocytes. The nonspecific PDE inhibitor pentoxifylline is able to inhibit both the
5 formation of oxygen free radicals and the phagocytic ability of neutrophilic granulocytes (Wenisch, C.; Zedtwitz-Liebenstein, K.; Parschalk, B. and Graninger, W.: Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability
10 assessed by flow cytometry, Clin. Drug Invest., 13(2):99-104, 1997).

Various PDE 4 inhibitors have already been disclosed. These are primarily xanthine derivatives, rolipram
15 analogs or nitraquazone derivatives (review in: Karlsson, J.A., Aldos, D., Phosphodiesterase 4 inhibitors for the treatment of asthma, Exp. Opin. Ther. Patents 1997, 7: 989-1003). It has not been possible to date for any of these compounds to be used
20 clinically. It was unavoidably found that the known PDE4 inhibitors also have various side effects, such as nausea and emesis, which it has not to date been possible to suppress adequately. It is therefore necessary to discover novel PDE4 inhibitors with
25 improved therapeutic index.

Indol-3-ylglyoxylamides and processes for preparing them have already been described several times. In all cases, indoles unsubstituted in position 3, which are
30 synthesized by substitution in position 1 of a commercially available indole, were converted by reaction with oxalyl halides into indol-3-ylglyoxylyl halides which subsequently afford, by reaction with ammonia or with primary or secondary amines, the
35 corresponding indol-3-ylglyoxylamides. (Scheme 1)

Scheme 1:



5 Thus, US patents 2,825,734 and 3,188,313 describe various indol-3-ylglyoxylamides which are prepared by the manner depicted in Scheme 1. These compounds were used as intermediates for preparing indole derivatives produced by reductions. US patent 3,642,803 also
10 describes indol-3-ylglyoxylamides.

The preparation of 5-methoxyindol-3-ylglyoxylamides is described in *Farmaco* 22 (1967), 229-244. Again there is reaction of the indole derivative used with oxalyl
15 chloride, and the resulting indol-3-ylglyoxyl chloride is reacted with an amine.


In addition, US patent 6,008,231 describes indol-3-ylglyoxylamides and processes for preparing them. Once
20 again, the reaction steps and conditions depicted in Scheme 1 are used.

Substituted 5-hydroxyindolylglyoxylamides and 6-hydroxyindolylglyoxylamides and processes for preparing
25 them and the use thereof as PDE4 inhibitors were described for the first time in DE patent application 198 18 964 A1.

7-Azaindol-3-ylglyoxylamides are disclosed as PDE4
30 inhibitors in DE patent application 100 53 275 A1, which also describes their preparation and use as therapeutic agents.

4- and 7-Hydroxyindole derivatives, their preparation and use as PDE4 inhibitors are proposed in DE patent application 102 53 426.8.

5 The invention relates to substituted hydroxyindoles of the general formula 1



in which

- 10 R^1
- (i) is $-C_{1-10}$ -alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by
- 15 $-OH$, $-SH$, $-NH_2$, $-NHC_{1-6}$ -alkyl, $-N(C_{1-6}$ -alkyl) $_2$, $-NHC_{6-14}$ -aryl, $-N(C_{6-14}$ -aryl) $_2$, $-N(C_{1-6}$ -alkyl)(C_{6-14} -aryl), $-NO_2$, $-CN$, $-F$, $-Cl$, $-Br$, $-I$, $-O-C_{1-6}$ -alkyl, $-O-C_{6-14}$ -aryl, $-S-C_{1-6}$ -alkyl, $-S-C_{6-14}$ -aryl, $-SO_3H$, $-SO_2C_{1-6}$ -alkyl, $-SO_2C_{6-14}$ -aryl, $-OSO_2C_{1-6}$ -alkyl, $-OSO_2C_{6-14}$ -aryl, $-COOH$, $-(CO)C_{1-5}$ -alkyl, $-COO-C_{1-5}$ -alkyl, $-O(CO)C_{1-5}$ -alkyl, by mono-, bi-
- 20 or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6
- 25 heteroatoms, which are preferably N, O and S, where the C_{6-14} -aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by
- 30 $-C_{1-6}$ -alkyl, $-OH$, $-NH_2$, $-NHC_{1-6}$ -alkyl, $-N(C_{1-6}$ -alkyl) $_2$, $-NO_2$, $-CN$, $-F$, $-Cl$, $-Br$, $-I$, $-O-C_{1-6}$ -alkyl, $-S-C_{1-6}$ -alkyl, $-SO_3H$, $-SO_2C_{1-6}$ -alkyl,

5 -OSO₂C₁₋₆-alkyl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl or/and -O(CO)C₁₋₅-alkyl, and where the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or/and -COOH, or

 (ii) is -C₂₋₁₀-alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally
10 mono- or polysubstituted by -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC₆₋₁₄-aryl, -N(C₆₋₁₄-aryl)₂, -N(C₁₋₆-alkyl)(C₆₋₁₄-aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -O-C₆₋₁₄-aryl, -S-C₁₋₆-alkyl, -S-C₆₋₁₄-aryl, -SO₃H,
15 -SO₂C₁₋₆-alkyl, -SO₂C₆₋₁₄-aryl, -OSO₂C₁₋₆-alkyl, -OSO₂C₆₋₁₄-aryl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl, -O(CO)C₁₋₅-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by
20 mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,
 where the C₆₋₁₄-aryl groups and the carbocyclic and heterocyclic substituents in turn may
25 optionally be substituted one or more times by -C₁₋₆-alkyl, -OH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, -SO₃H, -SO₂C₁₋₆-alkyl, -OSO₂C₁₋₆-alkyl, -COOH, -(CO)C₁₋₅-alkyl, -COO-C₁₋₅-alkyl or/and -O(CO)-C₁₋₅-alkyl,
30 and where the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by
35 -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or/and -COOH,

R² is hydrogen or -C₁₋₃-alkyl,

R^3 , R^4 and R^5 are hydrogen or a hydroxyl group, where at least one of these substituents must be a hydroxyl group,

5 R^6 and R^7 may be identical or different and are hydrogen, $-C_{1-6}$ -alkyl, $-OH$, $-SH$, $-NH_2$, $-NHC_{1-6}$ -alkyl, $-N(C_{1-6}$ -alkyl) $_2$, $-NO_2$, $-CN$, $-SO_3H$, $-SO_3-C_{1-6}$ -alkyl, $-COOH$, $-COO-C_{1-6}$ -alkyl, $-O(CO)-C_{1-5}$ -alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-O-C_{1-6}$ -alkyl, $-S-C_{1-6}$ -alkyl, $-phenyl$ or $-pyridyl$, where the
10 phenyl or pyridyl substituents in turn may optionally be substituted one or more times by $-C_{1-3}$ -alkyl, $-OH$, $-SH$, $-NH_2$, $-NHC_{1-3}$ -alkyl, $-N(C_{1-3}$ -alkyl) $_2$, $-NO_2$, $-CN$, $-SO_3H$, $-SO_3C_{1-3}$ -alkyl, $-COOH$, $-COOC_{1-3}$ -alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-O-C_{1-3}$ -alkyl, $-S-C_{1-3}$ -alkyl, or/and $-O(CO)C_{1-3}$ -
15 alkyl, and where the alkyl substituents in turn may optionally be substituted one or more times by $-OH$, $-SH$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-I$, $-SO_3H$, $-SO_3C_{1-3}$ -alkyl, $-COOH$, $-COOC_{1-3}$ -alkyl, $-O-C_{1-3}$ -alkyl, $-S-C_{1-3}$ -alkyl or/and $-O(CO)-C_{1-3}$ -alkyl.

20

Preferred compounds of the formula 1 are those in which R^1 is an optionally substituted C_{1-4} -alkyl radical, particularly preferably a C_1 radical, with a cyclic substituent. The cyclic substituents are preferably
25 C_{3-8} -cycloalkyl groups or C_{5-6} -aryl or heteroaryl radicals which may have at least one substituent selected from halogen, i.e. $-F$, $-Cl$, $-Br$ or $-I$, $-OH$, $-NO_2$, $-CN$ and $-CF_3$.

30 Of the compounds of formula 1 the invention preferably relates to those compounds in which R^2 is hydrogen or a methyl group.

Of the compounds of formula 1 the invention preferably
35 relates to those compounds in which R^5 is a hydroxyl group and R^3 and R^4 are hydrogen.

Of the compounds of formula 1 the invention preferably relates to those compounds in which at least one of R^6

or R^7 is a halogen atom. R^6 and R^7 are preferably particularly halogen atoms. The compounds mentioned in the experimental examples are also particularly preferred.

5

The invention further relates to physiologically tolerated salts of the compounds of formula 1.

10 The physiologically tolerated salts are obtained in a conventional way by neutralizing the bases with inorganic or organic acids or by neutralizing the acids with inorganic or organic bases. Examples of suitable inorganic acids are hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid, and examples of
15 suitable organic acids are carboxylic or sulfonic acids, such as acetic acid, tartaric acid, lactic acid, propionic acid, glycolic acid, malonic acid, maleic acid, fumaric acid, tannic acid, succinic acid, alginic acid, benzoic acid, 2-phenoxybenzoic acid, 2-
20 acetoxymethylbenzoic acid, cinnamic acid, mandelic acid, citric acid, malic acid, salicylic acid, 3-aminosalicylic acid, ascorbic acid, embonic acid, nicotinic acid, isonicotinic acid, oxalic acid, amino acids, methanesulfonic acid, ethanesulfonic acid, 2-
25 hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid or naphthalene-2-sulfonic acid. Examples of suitable inorganic bases are sodium hydroxide solution, potassium hydroxide solution, ammonia, and suitable
30 organic bases are amines, but preferably tertiary amines such as trimethylamine, triethylamine, pyridine, N,N-dimethylaniline, quinoline, isoquinoline, α -picoline, β -picoline, γ -picoline, quinaldine or pyrimidine.

35

Physiologically tolerated salts of the compounds of formula 1 can additionally be obtained by converting derivatives having tertiary amino groups in a manner known per se with quaternizing agents into the

corresponding quaternary ammonium salts. Examples of suitable quaternizing agents are alkyl halides such as methyl iodide, ethyl bromide and n-propyl chloride, but also arylalkyl halides such as benzyl chloride or 2-phenylethyl bromide.

The invention further relates to the D form, the L form and D,L mixtures of compounds of the formula 1 which contain an asymmetric carbon atom, and in the case of a plurality of asymmetric carbon atoms, also the diastereomeric forms. Compounds of the formula 1 which contain asymmetric carbon atoms and usually result as racemates can be separated into the optically active isomers in a manner known per se, for example with an optically active acid. However, it is also possible to employ an optically active starting substance from the outset, in which case a corresponding optically active or diastereomeric compound is obtained as final product.

The compounds of the invention have been found to have pharmacologically important properties which can be utilized in therapy. The compounds of formula 1 can be employed alone, in combination with one another or in combination with other active ingredients.

The compounds of the invention are inhibitors of phosphodiesterase 4. It is therefore an aspect of this invention that the compounds of formula 1 and the salts thereof, and pharmaceutical preparations which comprise these compounds or salts thereof, can be used for the treatment of disorders in which inhibition of phosphodiesterase 4 is beneficial.

These disorders include, for example, inflammations of joints, including arthritis and rheumatoid arthritis, and other arthritic disorders such as rheumatoid spondylitis and osteoarthritis. Further possible uses are the treatment of patients suffering from

osteoporosis, sepsis, septic shock, Gram-negative sepsis, toxic shock syndrome, respiratory distress syndrome, asthma or other chronic pulmonary disorders, bone resorption disorders or transplant rejection
5 reactions or other autoimmune diseases such as lupus erythematosus, multiple sclerosis, glomerulonephritis and uveitis, insulin-dependent diabetes mellitus and chronic demyelination.

10 The compounds of the invention can additionally be employed for the therapy of infections such as viral infections and parasitic infections, for example for the therapy of malaria, leishmaniasis, infection-related fever, infection-related muscle pain, AIDS and
15 cachexia, and of non-allergic rhinitis.

The compounds of the invention can likewise be used for the therapy of hyperproliferative disorders, in particular of cancers, for example for the therapy of
20 melanomas, of breast cancer, lung cancer, bowel cancer, skin cancer and of leukemias.

The compounds of the invention can also be employed as bronchodilators and for the treatment of asthma, e.g.
25 for asthma prophylaxis.

The compounds of formula 1 are in addition inhibitors of the accumulation of eosinophils and the activity thereof. Accordingly, the compounds of the invention
30 can also be employed for disorders in which eosinophils are involved. These disorders include, for example, inflammatory respiratory tract disorders such as bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, eczemas, allergic
35 angiitis, eosinophil-mediated inflammations such as eosinophilic fasciitis, eosinophilic pneumonia and PIE syndrome (pulmonary infiltration with eosinophilia), urticaria, ulcerative colitis, Crohn's disease and

proliferative skin disorders such as psoriasis or keratosis.

It is an aspect of this invention that the compounds of
5 formula 1 and salts thereof are also able to inhibit
LPS-induced pulmonary neutrophilic infiltration in rats
in vivo. The pharmacologically significant properties
which have been found prove that the compounds of
formula 1 and salts thereof, and pharmaceutical
10 preparations which comprise these compounds or salts
thereof, can be utilized therapeutically for the
treatment of chronic obstructive pulmonary diseases.

The compounds of the invention additionally have
15 neuroprotective properties and can be used for the
therapy of diseases in which neuroprotection is
beneficial. Examples of such disorders are senile
dementia (Alzheimer's disease), memory loss,
Parkinson's disease, depression, strokes and
20 intermittent claudication.

Further possible uses of the compounds of the invention
are the prophylaxis and therapy of prostate disorders
such as, for example, benign prostate hyperplasia,
25 polyuria, nocturia, and the treatment of incontinence,
of colic induced by urinary calculi, and of male and
female sexual dysfunctions.

Finally, the compounds of the invention can likewise be
30 used to inhibit the development of drug dependence on
repeated use of analgesics such as, for example,
morphine, and to reduce the development of tolerance on
repeated use of these analgesics.

35 The drug products are produced by using an effective
dose of the compounds of the invention or salts
thereof, in addition to conventional adjuvants,
carriers and additives. The dosage of the active
ingredients may vary depending on the route of

administration, age and weight of the patient, nature and severity of the disorders to be treated and similar factors. The daily dose may be given as a single dose to be administered once a day, or divided into 2 or more daily doses, and is usually 0.001-100 mg. Daily dosages of 0.1-50 mg are particularly preferably administered.

Oral, parenteral, intravenous, transdermal, topical, inhalational and intranasal preparations are suitable as administration form. Topical, inhalational and intranasal preparations of the compounds of the invention are particularly preferably used. Conventional pharmaceutical presentations such as tablets, coated tablets, capsules, dispersible powders, granules, aqueous solutions, aqueous or oily suspensions, syrup, solutions or drops are used.

Solid drug forms may comprise inert ingredients and carriers such as, for example, calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatin, guar gum, magnesium stearate or aluminum stearate, methylcellulose, talc, colloidal silicas, silicone oil, high molecular weight fatty acids (such as stearic acid), agar-agar or vegetable or animal fats and oils, solid high molecular weight polymers (such as polyethylene glycol); preparations suitable for oral administration may, if desired, comprise additional flavorings and/or sweeteners.

Liquid drug forms can be sterilized and/or where appropriate comprise excipients such as preservatives, stabilizers, wetting agents, penetrants, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols to control the osmotic pressure or for buffering and/or viscosity regulators.

Examples of such additions are tartrate buffer and citrate buffer, ethanol, complexing agents (such as ethylenediaminetetraacetic acid and its non-toxic salts). Suitable for controlling the viscosity are high
5 molecular weight polymers such as, for example, liquid polyethylene oxide, microcrystalline celluloses, carboxymethylcelluloses, polyvinylpyrrolidones, dextrans or gelatin. Examples of solid carriers are starch, lactose, mannitol, methylcellulose, talc,
10 colloidal silicas, higher molecular weight fatty acids (such as stearic acid), gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high molecular weight polymers such as polyethylene glycol.

15

Oily suspensions for parenteral or topical uses may be vegetable synthetic or semisynthetic oils such as, for example, liquid fatty acid esters with in each case 8 to 22 C atoms in the fatty acid chains, for example
20 palmitic, lauric, tridecylic, margaric, stearic, arachic, myristic, behenic, pentadecylic, linoleic, elaidic, brasidic, erucic or oleic acid, which are esterified with monohydric to trihydric alcohols having 1 to 6 C atoms, such as, for example, methanol,
25 ethanol, propanol, butanol, pentanol or isomers thereof, glycol or glycerol. Examples of such fatty acid esters are commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic/capric esters of
30 saturated fatty alcohols, polyoxyethylene glycerol trioleates, ethyl oleate, waxy fatty acid esters such as artificial duck preen gland fat, coco fatty acid isopropyl ester, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol
35 fatty acid esters inter alia. Likewise suitable are silicone oils differing in viscosity or fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, fatty acids such as, for example, oleic acid. It is additionally

possible to use vegetable oils such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil.

- 5 Suitable solvents, gel formers and solubilizers are water or water-miscible solvents. Suitable examples are alcohols such as, for example, ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl Cellosolve, Cellosolve, esters, morpholines, dioxane, dimethyl sulfoxide, dimethylformamide, tetrahydrofuran, cyclohexanone etc.
- 10
- 15 Film formers which can be used are cellulose ethers able to dissolve or swell both in water and in organic solvents, such as, for example, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose or soluble starches.
- 20
- Combined forms of gel formers and film formers are likewise perfectly possible. Ionic macromolecules are used in particular for this purpose, such as, for example, sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid and salts thereof, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as sodium salt, gum arabic, xanthan gum, guar gum or carrageenan.
- 25
- 30 Further formulation aids which can be employed are: glycerol, paraffin of differing viscosity, triethanolamine, collagen, allantoin, novantisolic acid.
- 35 It may also be necessary to use surfactants, emulsifiers or wetting agents for the formulation, such as, for example, Na lauryl sulfate, fatty alcohol ether sulfates, di-Na N-lauryl- β -iminodipropionate, polyethoxylated castor oil or sorbitan monooleate,

sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glyceryl monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether, cetyltrimethylammonium chloride or
5 mono/dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts.

Stabilizers such as montmorillonites or colloidal silicas to stabilize emulsions or to prevent
10 degradation of the active substances, such as antioxidants, for example tocopherols or butylated hydroxyanisole, or preservatives such as p-hydroxybenzoic esters, may likewise be necessary where appropriate to prepare the desired formulations.


15 Preparations for parenteral administration may be present in separate dose unit forms such as, for example, ampoules or vials. Solutions of the active ingredient are preferably used, preferably aqueous solutions and especially isotonic solutions, but also
20 suspensions. These injection forms can be made available as finished product or be prepared only immediately before use by mixing the active compound, e.g. the lyophilisate, where appropriate with further solid carriers, with the desired solvent or suspending
25 agent.

Intranasal preparations may be in the form of aqueous or oily solutions or of aqueous or oily suspensions. They may also be in the form of lyophilisates which are
30 prepared before use with the suitable solvent or suspending agent.


The manufacture, bottling and closure of the products takes place under the usual antimicrobial and aseptic
35 conditions.

The invention further relates to processes for preparing the compounds of the invention.

The compounds of the general formula 1 with the meanings of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 described above are prepared according to the invention



5 by oxidizing indol-3-ylglyoxylamides of the formula 2 having the same meaning of R^1 , R^2 and R^5



10 in which R^3 , R^4 and R^5 are H or $-OR^8$, where at least one of these substituents must be $-OR^8$ and R^8 is a leaving group, e.g. alkyl, cycloalkyl, arylalkyl, acyl, alcoxycarbonyl, aryloxycarbonyl, aminocarbonyl, N-substituted aminocarbonyl, silyl and sulfonyl groups, and complexing agents such as compounds of boric acid
15 or phosphoric acid, and covalently or co-ordinately bonded metals, such as zinc, aluminum or copper,

in a manner known per se by treatment with an oxidizing agent, e.g. an organic peracid, preferably with m-chloroperbenzoic acid or/and peracetic acid, to the
20 compounds of the invention of the formula 1 in which R^3 , R^4 and R^5 are H or $-OR^8$, where at least one of these substituents must be $-OR^8$.

The compounds of the invention of the formula 1 are liberated by eliminating the leaving group R^8 still present in R^3 and/or R^4 and/or R^5 .

5 The substituent $-R^8$ is eliminated by employing both acids and bases, such as, for example, hydrobromic acid, hydrochloric acid or hydriodic acid, or sodium hydroxide solution, potassium hydroxide solution, and sodium carbonate or potassium carbonate, but also
10 activating Lewis acids such as, for example, $AlCl_3$, BF_3 , BBr_3 or $LiCl$. The elimination reaction takes place in each case in the absence or presence of additional activators such as, for example, ethane-1,2-dithiol or benzyl mercaptan, and ether cleavages using hydrogen,
15 under elevated pressure or atmospheric pressure, in the presence of a suitable catalyst such as, for example, palladium or iridium catalysts.

Examples

20

Example 1:

**Preparation of N-(3,5-Dichloro-1-oxopyridin-4-yl)-
[1-(4-fluorobenzyl)-7-hydroxyindol-3-
25 yl]glyoxylamide**

12 g of N-(3,5-dichloropyridin-4-yl)-[7-benzyloxy-1-(4-fluorobenzyl)-indol-3-yl]glyoxylamide are dissolved in 250 ml of methylene chloride. While stirring, a
30 solution of 11.4 g of m-chloroperbenzoic acid (77%) in 30 ml of acetic acid is added dropwise. The reaction mixture is stirred at room temperature for 7 days. The reaction mixture is adjusted to pH 8 by adding a saturated potassium carbonate solution. It is stirred
35 vigorously for another hour. Then the phases are separated, and the organic phase is washed with 100 ml of water. The solvent is distilled out in vacuo. The residue is stirred with 50 ml of isopropanol. The

crystals are removed and boiled with 50 ml of ethandol.
The crystalline product is removed and dried.


Yield: 2.1 g (16.9% of theory)

5 1.8 g of the N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-benzyloxy-1-(4-fluorobenzyl)indol-3-yl] glyoxylamide are dissolved in 50 ml of dichloromethane. A solution of 0.7 ml of BBr_3 in 50 ml of dichloromethane is added dropwise while heating to reflux. The mixtures is then
10 stirred while heating to reflux for a further 3 hours. After cooling to 10°C , 50 ml of a 1M NaHCO_3 solution are added, thus resulting in a pH of 8-9. The temperature must be kept below 20°C during this. The mixture is then stirred for 3 hours. The crystallized
15 product is filtered off with suction, washed with water and dried. The crude product is recrystallized from ethanol.

Yield: 1.0 g (66.2% of theory)

20 Melting point: $241-243^\circ\text{C}$

Numerous further compounds of the formula 1 can be prepared by using the indicated process for preparation, of which the following are cited as
25 examples:



(1)

Compound	-R ¹	-R ²	-R ³	-R ⁴	-R ⁵	-R ⁶	-R ⁷
1	4-Fluorobenzyl-	-H	-H	-H	-OH	3-Cl	5-Cl
2	4-Chlorobenzyl-	-H	-H	-H	-OH	3-Cl	5-Cl
3	4-Fluorobenzyl-	-H	-H	-H	-OH	3-Cl	5-Cl
4	2,4-Dichlorobenzyl-	-H	-H	-H	-OH	3-Cl	5-Cl
5	3-Nitrobenzyl-	-H	-H	-H	-OH	-H	-H
6	2,6-Difluorobenzyl-	-H	-OH	-H	-H	3-Cl	5-Cl
7	Isobutyl-	-H	-H	-H	-OH	3-Cl	5-Cl
8	Cyclopropylmethyl-	-H	-H	-H	-OH	3-Cl	5-Cl
9	4-Hydroxybenzyl	-H	-H	-H	-OH	3-Cl	5-Cl
10	Isobutyl-	-H	-H	-H	-OH	3-Cl	5-Cl
11	Cyclopropylmethyl-	-H	-H	-H	-OH	3-Cl	5-Cl
12	4-Hydroxybenzyl-	-H	-H	-H	-OH	3-Cl	5-Cl
13	4-Fluorobenzyl-	-CH ₃	-H	-H	-OH	3-Cl	5-Cl
14	4-Fluorobenzyl-	-H	-H	-OH	-H	3-Cl	5-Cl
15	2-Chlorobenzyl-	-H	-H	-OH	-H	-H	-H

The compounds of the invention are strong inhibitors of phosphodiesterase 4. Their therapeutic potential is demonstrated *in vivo* for example through the inhibition of the asthmatic late-phase reaction (eosinophilia) and through the inhibition of LPS-induced neutrophilia in rats.

Example 2: Phosphodiesterase 4 inhibition

PDE4 activity is determined using enzyme preparations from human polymorphonuclear lymphocytes (PMNL). Human blood (buffy coats) was anticoagulated with citrate. A centrifugation at 700 x g at room temperature (RT) for

20 minutes separates the platelet-rich plasma in the supernatant from the erythrocytes and leukocytes. The PMNLs for the PDE 4 determination are isolated by a subsequent dextran sedimentation and in gradient centrifugation with Ficoll-Paque. After the cells have been washed twice, the erythrocytes which are still present are lysed by adding 10 ml of hypotonic buffer (155 mM NH_4Cl , 10 mM NaHCO_3 , 0.1 mM EDTA, pH=7.4) at 4°C within 6 minutes. The still intact PMNLs are then washed twice with PBS and lysed by ultrasound. The supernatant from a centrifugation at 4°C and 48000 x g for one hour contains the cytosolic fraction of PDE 4 and is employed for the PDE 4 measurements.

The phosphodiesterase activity is assayed using a modified Amersham Pharmacia Biotech method, an SPA (scintillation proximity assay).

The reaction mixtures contain buffer (50 mM Tris-HCl (pH 7.4), 5 mM MgCl_2 , 100 μM cGMP), the inhibitors in variable concentrations and the appropriate enzyme preparation. The reaction is started by adding the substrate, 0.5 μM [^3H]-cAMP. The final volume is 100 μl . Test substances are made up as stock solutions in DMSO. The DMSO concentration in the reaction mixture is 1% v/v. The PDE activity is unaffected at this DMSO concentration. After the reaction has been started by adding substrate, the samples are incubated at 37°C for 30 minutes. The reaction is stopped by adding a defined amount of SPA beads, and the samples are counted after one hour in a Beta counter. The nonspecific enzymic activity (the blank) is determined in the presence of 100 μM rolipram and subtracted from the test results. The incubation mixtures for the PDE4 assay contain 100 μM cGMP in order to inhibit any contamination by PDE 3.

The IC_{50} values for inhibition of phosphodiesterase 4 determined for the compounds of the invention were in

the range from 10^{-10} to 10^{-5} M. The selectivity factor in relation to PDE of types 3, 5 and 7 is from 100 to 10.000.

5 **Example 3:**

Inhibition of late-phase eosinophilia 48 h after inhalational ovalbumin challenge in actively sensitized brown Norway rats

- 10 Inhibition of the pulmonary eosinophilic infiltration by the substances of the invention is tested on male brown Norway rats (200-250 g) actively sensitized against ovalbumin (OVA). The sensitization takes place by subcutaneous injections of a suspension of 10 µg of
- 15 OVA together with 20 mg of aluminum hydroxide as adjuvant in 0.5 ml of physiological saline per animal on day 1, 14 and 21. In addition to this, the animals receive at the same time i.p. injections of 0.25 ml of *Bordetella pertussis* vaccine dilution per animal. On
- 20 day 28 of the test, the animals are placed singly in open 1 l Plexiglas boxes connected to a head/nose exposure apparatus. The animals are exposed to an aerosol of 1.0% ovalbumin suspension (allergen challenge). The ovalbumin aerosol is generated by a
- 25 nebulizer (Bird micro nebulizer, Palm Springs CA, USA) operated with compressed air (0.2 MPa). The exposure time is 1 hour, with an aerosol of 0.9% saline being nebulized for normal controls likewise for 1 hour.
- 30 48 hours after the allergen challenge there is a massive migration of eosinophilic granulocytes into the lungs of the animals. At this time, the animals are anesthetized with an overdose of ethylurethane (1.5 g/kg of body weight i.p.), and a bronchoalveolar
- 35 lavage (BAL) is carried out with 3 x 4 ml of Hank's balanced solution. The total cell count and the number of eosinophilic granulocytes in the pooled BAL liquid are subsequently determined using an automatic cell differentiation instrument (Bayer Diagnostics Technicon

H1E). The eosinophils (EOS) in the BAL are calculated for each animal in $10^6/\text{animal}$: $\text{EOS}/\mu\text{l} \times \text{BAL recovery (ml)} = \text{EOS/animal}$.

- 5 Two control groups (nebulization of physiological saline and nebulization of OVA solution) are included in each test.

The percentage inhibition of the eosinophilia in the
10 test group treated with the substance is calculated by the following formula:

$$\{((\text{OVAC} - \text{SC}) - (\text{OVAD} - \text{SC})) / (\text{OVAC} - \text{SC})\} \times 100\% = \%$$

% inhibition

15

(SC = control group treated with vehicle and challenged with 0.9% saline; OVAC = control group treated with vehicle and challenged with 1% ovalbumin suspension; OVAD = test group treated with substance and challenged
20 with 1% ovalbumin suspension)

The test substances are administered intraperitoneally or orally as suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethylcellulose 2 hours before the
25 allergen challenge. The control groups are treated with the vehicle in accordance with the test substance application form.

The compounds of the invention inhibit the late-phase
30 eosinophilia by 30% to 100% after intraperitoneal administration of 10 mg/kg and by 30% to 80% after oral administration of 30 mg/kg.

The compounds of the invention are thus particularly
35 suitable for producing drug products for the treatment of disorders associated with the effect of eosinophils.

Example 4:

Inhibition of lipopolysaccharide (LPS)-induced pulmonary neutrophilia in Lewis rats

5 The inhibition of pulmonary neutrophil infiltration by the substances of the invention is tested on male Lewis rats (250-350 g). On the day of the test, the animals are placed singly in open 1 l Plexiglas boxes connected to a head/nose exposure apparatus. The animals are
10 exposed to an aerosol from a lipopolysaccharide suspension (100 µg of LPS/ml of 0.1% hydroxylamine solution) in PBS (LSP provocation). The LPS/hydroxylamine aerosol is generated by a nebulizer (Bird micro nebulizer, Palm Springs CA, USA) operated
15 by compressed air (0.2 MPa). The exposure time is 40 minutes, with an aerosol being nebulized from 0.1% hydroxylamine solution in PBS for normal controls, likewise for 40 minutes.

20 6 hours after the LPS provocation there is a maximal, massive migration of neutrophilic granulocytes into the lungs of the animals. At this time, the animals are anesthetized with an overdose of ethylurethane (1.5 g/kg of body weight i.p.), and a bronchoalveolar
25 lavage (BAL) is carried out with 3 x 4 ml of Hank's balanced solution. The total cell count and the number of neutrophilic granulocytes in the pooled BAL liquid are subsequently determined using an automatic cell differentiation apparatus (Bayer Diagnostics Technicon
30 H1E). The neutrophils (NEUTRO) in the BAL are calculated for each animal in $10^6/\text{animal}$: $\text{NEUTRO}/\mu\text{l} \times \text{BAL recovery (ml)} = \text{NEUTRO}/\text{animal}$.

Two control groups (nebulization of 0.1% hydroxylamine
35 solution in PBS and nebulization of 100 µg of LPS/ml of 0.1% hydroxylamine solution in PBS) are included in each test.

The percentage inhibition of the neutrophilia in the test group treated with the substance is calculated by the following formula:

5
$$\{((\text{LPSC} - \text{SC}) - (\text{LPSD} - \text{SC})) / (\text{LPSC} - \text{SC})\} \times 100\% =$$

 % inhibition

SC = control group treated with vehicle and challenged with 0.1% hydroxylamine solution; LPSC = control group
10 treated with vehicle and challenged with LPS (100 µg/ml of 0.1% hydroxylamine solution); LPSD = test group treated with substance and challenged with LPS (100 µg/ml of 0.1% hydroxylamine solution).

15 The test substances are administered orally as suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethylcellulose 2 hours before the LPS provocation. The control groups are treated with the vehicle in accordance with the test substance
20 administration form.

The compounds of the invention inhibit the neutrophilia by 30% to 90% after oral administration of 10 mg/kg and are thus particularly suitable for producing drug
25 products for the treatment of disorders associated with the effect of neutrophils.